Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clarity Pharmaceuticals Ltd (CU6.AX)
AUD2.45
+0.05 (+2.08%)
AU ASX Healthcare Medical - Specialties
Address
National Innovation Centre 2015
Sydney, NSW, AU
Sydney, NSW, AU
CEO
Michelle Parker
Website
claritypharmaceuticals.com
IPO
2021-08-25
ISIN AU0000165375
Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD2.45
+0.05 (+2.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.17
Float Shares
229.53M
Free Float %
61.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.47% | -9.45% | -12.01% | -31.02% | -31.02% | -26.33% | +15.28% | +230.83% | +66.00% | +66.00% | +66.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.45
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
22.17
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-17.8% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%-33.3% Q4'25: -129.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-700.6%
-
EBIT margin Medical - Specialties: +12.6%-730.2%
-
ROIC Medical - Specialties: +6.6%-1,130.4% Q4'25: -3,465.1% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+16.9% Q4'25: +38.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.00× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 3 Rev. Ana. 4 EPS Ana. |
Jun 2027 3 Rev. Ana. 4 EPS Ana. |
Jun 2028 3 Rev. Ana. 4 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
6.46M
est: 6.55M (-1.5%)
|
9.80M
est: 3.93M (+149.2%)
|
11.51M
est: 5.10M (+125.6%)
|
9.46M
est: 3.93M (+140.8%)
|
3.25M
3.25M – 3.25M
-17.3% YoY
|
7.20M
7.20M – 7.20M
+121.5% YoY
|
154.08M
154.08M – 154.08M
+2,039.9% YoY
|
632.16M
632.16M – 632.16M
+310.3% YoY
|
| EBITDA |
-30.15M
est: -6.55M (-360.0%)
|
-34.20M
est: -3.93M (-769.5%)
|
-44.65M
est: -5.10M (-775.4%)
|
-68.91M
est: -3.93M (-1,653.2%)
|
-3.25M
-3.25M – -3.25M
+17.3% YoY
|
-7.20M
-7.20M – -7.20M
-121.5% YoY
|
-154.08M
-154.08M – -154.08M
-2,039.9% YoY
|
-632.16M
-632.16M – -632.16M
-310.3% YoY
|
| EBIT |
-30.20M
est: -6.55M (-360.7%)
|
-34.30M
est: -3.93M (-772.0%)
|
-44.80M
est: -5.10M (-778.4%)
|
-69.09M
est: -3.93M (-1,657.9%)
|
-3.25M
-3.25M – -3.25M
+17.3% YoY
|
-7.20M
-7.20M – -7.20M
-121.5% YoY
|
-154.08M
-154.08M – -154.08M
-2,039.9% YoY
|
-632.16M
-632.16M – -632.16M
-310.3% YoY
|
| Net Income |
-23.75M
est: -44.55M (+46.7%)
|
-24.60M
est: -24.60M (+0.0%)
|
-42.32M
est: -39.48M (-7.2%)
|
-64.30M
est: -48.62M (-32.2%)
|
-89.65M
-102.20M – -77.11M
-84.4% YoY
|
-102.35M
-119.66M – -85.03M
-14.2% YoY
|
-36.09M
-92.45M – 37.91M
+64.7% YoY
|
196.88M
196.88M – 196.88M
+645.5% YoY
|
| SGA |
10.69M
est: 7.17M (+49.1%)
|
4.60M
est: 4.30M (+7.1%)
|
10.52M
est: 5.58M (+88.7%)
|
11.68M
est: 4.30M (+171.7%)
|
3.55M
3.55M – 3.55M
-17.3% YoY
|
7.87M
7.87M – 7.87M
+121.5% YoY
|
168.50M
168.50M – 168.50M
+2,039.9% YoY
|
691.34M
691.34M – 691.34M
+310.3% YoY
|
| EPS |
-0.10
est: -0.14 (+31.5%)
|
-0.09
est: -0.09 (-5.7%)
|
-0.15
est: -0.12 (-21.3%)
|
-0.20
est: -0.16 (-28.3%)
|
-0.29
-0.32 – -0.24
-87.9% YoY
|
-0.32
-0.37 – -0.27
-8.3% YoY
|
-0.09
-0.29 – 0.12
+72.5% YoY
|
0.62
0.62 – 0.62
+806.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-119.50M
OE per share TTM
-0.36
Owner's Yield
-13.19%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 41 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.29% | 250.9K | 0.55% |
| 2 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.13% | 1.06M | 0.30% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 295.0K | 0.40% |
| 4 | Vanguard Australian Shares Index ETF VAS.AX | 0.03% | 5.48M | 0.07% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 999.5K | 0.06% |
| 6 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 29.3K | 0.83% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.84M | 0.06% |
| 8 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.01% | 1.76M | 0.40% |
| 9 | iShares Core MSCI Pacific ETF IPAC | 0.01% | 139.5K | 0.09% |
| 10 | iShares MSCI World Small Cap UCITS ETF WSML.L | 0.00% | 372.4K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-7.9K
Shares Outstanding
372.97M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alan John Taylor | Executive Chairman | 2M | — |
| Michelle Parker | Chief Executive Officer, MD & Executive Director | 799.3K | female |
| Colin David Biggin | Chief Operating Officer | 759.6K | — |
| David K. Green BEc. | Chief Financial Officer | 495.3K | male |
| Ellen van Dam | Chief Scientific Officer | 195.4K | — |
| Othon Gervasio | Chief Medical Officer | — | — |
| Shaemus Gleason | Executive Vice President of Operations | — | male |
| Chris Horvath | Chief Commercial Officer | — | male |
| Eva Lengyelova | Executive Vice President of Clinical Development | — | female |
| Lisa Sadetskaya | Director of Corporate Communications. | — | female |
| Mary Bennett | Head of People & Culture | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CU6.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
